Phase 3 Readout~month

Phase 3 Topline: Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Dep

Name: Phase 3 Topline: Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Dep
Start: 2027-06-01

June 1, 2027

Company: Neumora Therapeutics, Inc. (NMRA)
Drug: major
Indication: Major Depressive Disorder

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants With Major Dep — NMRA Phase 3 Readout | BioSniper